News - Resverlogix Corp.

News

To receive future news releases direct to your inbox, subscribe by emailing ir@resverlogix.com.

Historical news and financial information can also be found at www.sedar.com under the Company’s profile.

2021 2020 2019 2018 2017 2016 2015 2014

Resverlogix to Present at Upcoming Conferences

October 13, 2021

Resverlogix Receives Ethics Approval for Canadian Sites in Apabetalone COVID-19 Clinical Trial

October 12, 2021

Study Demonstrates Resverlogix’s Apabetalone Treatment Significantly Improves Cognition and Reduces Cognitive Decline Among Patients with Both Cardiovascular Disease and Diabetes Mellitus

September 13, 2021

Resverlogix Announces Apabetalone Meets Primary Endpoint in a Pulmonary Arterial Hypertension Pilot Study

September 8, 2021

Resverlogix Announces Management Change

Resverlogix Announces Voting Results from the 2021 Meeting of Shareholders

Resverlogix and EVERSANA Announce Partnership to Support the Pending Launch of the Initial Commercialization of Apabetalone for COVID-19 in the United States and Canada

Resverlogix Announces US$6 Million Debenture Financing

Resverlogix’s Apabetalone Demonstrates a Medical First in Patients with Chronic Kidney Disease

Apabetalone’s Positive Impact on COVID-19 in Human Lung Cells Published in Biomedicines

Health Canada Issues Resverlogix Authorization to Begin Immediate Clinical Studies of Apabetalone for COVID-19

Apabetalone’s Beneficial Effects on COVID-19 Published in Prestigious Scientific Journal Cell

Apabetalone Treatment Prevents COVID-19 Infection of Human Lung Cells

Resverlogix Announces Change in Fiscal Year-End to December 31

New Published Evidence of Apabetalone’s Beneficial Effects on COVID-19

Resverlogix Reschedules Update Webcast and Conference Call

January 27, 2021

Resverlogix Announces Update Webcast and Conference Call

January 18, 2021

Apabetalone’s Positive Effect on Hospitalized Patients Involving Heart Failure

January 12, 2021